Denosumab中止。

IF 4.2 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Anne Sophie Sølling, Elena Tsourdi, Torben Harsløf, Bente L Langdahl
{"title":"Denosumab中止。","authors":"Anne Sophie Sølling,&nbsp;Elena Tsourdi,&nbsp;Torben Harsløf,&nbsp;Bente L Langdahl","doi":"10.1007/s11914-022-00771-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.</p><p><strong>Recent findings: </strong>Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss. During this phase of high bone turnover, an increased risk of fractures has been reported. Therefore, treatment with DMAB could be considered life-long. However, side-effects may prompt the need for discontinuation and moreover, treatment with DMAB may have increased BMD to levels where continuing treatment does not provide further fracture risk reduction. Patients stopping DMAB should be offered subsequent antiresorptive treatment with an intense monitoring regimen during the initial year as most of the bone loss occurs within these initial 12 months. In this review, we evaluated the literature published over the past 1 to 3 years investigating DMAB withdrawal with focus on bone turnover markers, bone mineral density, and fracture risk and the transition to other anti-osteoporosis therapies. Furthermore, we summarized the current recommendations of international guidelines. In this review, we evaluated the literature published over the past 1 to 3 years investigating denosumab (DMAB) discontinuation and the transition to other anti-osteoporosis therapies. Additionally, we summarized the current recommendations of international guidelines.</p>","PeriodicalId":11080,"journal":{"name":"Current Osteoporosis Reports","volume":"21 1","pages":"95-103"},"PeriodicalIF":4.2000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Denosumab Discontinuation.\",\"authors\":\"Anne Sophie Sølling,&nbsp;Elena Tsourdi,&nbsp;Torben Harsløf,&nbsp;Bente L Langdahl\",\"doi\":\"10.1007/s11914-022-00771-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.</p><p><strong>Recent findings: </strong>Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss. During this phase of high bone turnover, an increased risk of fractures has been reported. Therefore, treatment with DMAB could be considered life-long. However, side-effects may prompt the need for discontinuation and moreover, treatment with DMAB may have increased BMD to levels where continuing treatment does not provide further fracture risk reduction. Patients stopping DMAB should be offered subsequent antiresorptive treatment with an intense monitoring regimen during the initial year as most of the bone loss occurs within these initial 12 months. In this review, we evaluated the literature published over the past 1 to 3 years investigating DMAB withdrawal with focus on bone turnover markers, bone mineral density, and fracture risk and the transition to other anti-osteoporosis therapies. Furthermore, we summarized the current recommendations of international guidelines. In this review, we evaluated the literature published over the past 1 to 3 years investigating denosumab (DMAB) discontinuation and the transition to other anti-osteoporosis therapies. Additionally, we summarized the current recommendations of international guidelines.</p>\",\"PeriodicalId\":11080,\"journal\":{\"name\":\"Current Osteoporosis Reports\",\"volume\":\"21 1\",\"pages\":\"95-103\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Osteoporosis Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11914-022-00771-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-022-00771-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 8

摘要

综述目的:综述denosumab停药的病理生理学、临床后果以及减轻其影响的方法。最近发现:denosumab (DMAB)治疗是可逆的,停药后骨转换迅速增加,随后出现骨质流失。据报道,在这个高骨转换阶段,骨折的风险增加。因此,DMAB治疗可以被认为是终身的。然而,副作用可能促使需要停药,而且,使用DMAB治疗可能会使骨密度增加到继续治疗不能进一步降低骨折风险的水平。停用DMAB的患者应在最初一年接受后续抗吸收治疗,并进行严格的监测方案,因为大多数骨质流失发生在最初的12个月内。在这篇综述中,我们评估了过去1到3年发表的研究DMAB停药的文献,重点是骨转换标志物、骨矿物质密度、骨折风险以及向其他抗骨质疏松疗法的过渡。此外,我们总结了目前国际准则的建议。在这篇综述中,我们评估了过去1到3年发表的关于denosumab (DMAB)停药和向其他抗骨质疏松治疗过渡的文献。此外,我们总结了当前国际指南的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Denosumab Discontinuation.

Purpose of review: To review the pathophysiology, the clinical consequences as well as way of mitigating the effects of denosumab discontinuation.

Recent findings: Treatment with denosumab (DMAB) is reversible and upon discontinuation there is a rapid increase in bone turnover and a subsequent bone loss. During this phase of high bone turnover, an increased risk of fractures has been reported. Therefore, treatment with DMAB could be considered life-long. However, side-effects may prompt the need for discontinuation and moreover, treatment with DMAB may have increased BMD to levels where continuing treatment does not provide further fracture risk reduction. Patients stopping DMAB should be offered subsequent antiresorptive treatment with an intense monitoring regimen during the initial year as most of the bone loss occurs within these initial 12 months. In this review, we evaluated the literature published over the past 1 to 3 years investigating DMAB withdrawal with focus on bone turnover markers, bone mineral density, and fracture risk and the transition to other anti-osteoporosis therapies. Furthermore, we summarized the current recommendations of international guidelines. In this review, we evaluated the literature published over the past 1 to 3 years investigating denosumab (DMAB) discontinuation and the transition to other anti-osteoporosis therapies. Additionally, we summarized the current recommendations of international guidelines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Osteoporosis Reports
Current Osteoporosis Reports Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
8.80
自引率
2.30%
发文量
44
期刊介绍: This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信